Takashi Misawa Selected Research

benzohydrol (benzhydrol)

5/2015	Structure-activity relationships of benzhydrol derivatives based on 1'-acetoxychavicol acetate (ACA) and their inhibitory activities on multiple myeloma cell growth via inactivation of the NF-κB pathway.
10/2008	Structural development of benzhydrol-type 1'-acetoxychavicol acetate (ACA) analogs as human leukemia cell-growth inhibitors based on quantitative structure-activity relationship (QSAR) analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takashi Misawa Research Topics

Disease

4	Neoplasms (Cancer) 01/2018 - 05/2015
2	Infections 01/2021 - 04/2015
2	Breast Neoplasms (Breast Cancer) 01/2018 - 01/2016
2	Leukemia 05/2015 - 10/2008
2	progressive familial intrahepatic 1 Cholestasis 06/2012 - 05/2012
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Obesity 01/2021
1	Bacterial Infections (Bacterial Infection) 12/2020
1	Alzheimer Disease (Alzheimer's Disease) 09/2020
1	Communicable Diseases (Infectious Diseases) 06/2019
1	Multiple Myeloma 05/2015
1	Acquired Immunodeficiency Syndrome (AIDS) 04/2015

Drug/Important Bio-Agent (IBA)

2	Antimicrobial PeptidesIBA 01/2021 - 06/2019
2	LigandsIBA 01/2021 - 01/2016
2	Biological ProductsIBA 09/2020 - 05/2015
2	Hormones (Hormone)IBA 01/2018 - 01/2017
2	1'-acetoxychavicol acetateIBA 05/2015 - 10/2008
2	benzohydrol (benzhydrol)IBA 05/2015 - 10/2008
1	Adenosine Monophosphate (AMP)IBA 12/2020
1	Peptides (Polypeptides)IBA 12/2020
1	AntioxidantsIBA 09/2020
1	Silybin (Lagosa)IBA 09/2020
1	milk-thistle extractIBA 09/2020
1	Estrogen ReceptorsIBA 01/2016
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 04/2015
1	GW 4064IBA 06/2012
1	Member 11 Subfamily B ATP Binding Cassette TransporterIBA 05/2012
1	Growth InhibitorsIBA 10/2008

Therapy/Procedure

2	Therapeutics 01/2018 - 10/2016